Posted by Michael Wonder on 30 Jan 2026
Highlights from the 26-29 January 2026 CHMP meeting
30 January 2026 - The EMA’s CHMP recommended six medicines for approval at its January 2026 meeting.
The committee recommended granting a marketing authorisation for Fylrevy (estetrol), a hormone replacement therapy for oestrogen deficiency symptoms in postmenopausal women. During menopause, the amount of oestrogen produced by a woman’s body drops.
